Live
- Ticket distribution: AAP's public feedback on 70 seats
- Since YSRCP Boycotting Assembly Session: Alliance MLAs told to play Opposition role too
- Reliance invests big in AP
- 2024 on track to be hottest year on record
- PM Modi’s visit to Solapur: Women applaud ‘Double-Engine’ government’s initiatives
- Nagarkurnool MLA Dr. Kuchukulla Rajesh Reddy Campaigning in Maharashtra Elections
- Wife Kills Husband with Her Lover: Details of Veldanda Murder Case Revealed by SP Gaikwad
- Strict Action on Violations of Food Rights: Telangana Food Commission Chairman Goli Srinivas Reddy
- Smooth Conduct of Group-3 Exams with Strict Security Measures: Collector Badavath Santosh
- Delhi HC orders cancellation of LOC issued against Ashneer Grover, wife
Natco Pharma files ANDA for Bosentan tablets
Drug firm Natco Pharma on Tuesday said it has submitted an abbreviated new drug application (ANDA) with the US health regulator for the generic version of Bosentan 32 mg tablets for oral suspension.
Hyderabad: Drug firm Natco Pharma on Tuesday said it has submitted an abbreviated new drug application (ANDA) with the US health regulator for the generic version of Bosentan 32 mg tablets for oral suspension.
Bosentan 32 mg tablets are sold by Actelion Pharmaceuticals US, Inc under the brand name Tracleer, Natco Pharma said.
The company has filed the ANDA with Para IV certification with the US Food and Drug Administration (USFDA), it added.
"Natco believes that its ANDA is possibly the sole first-to-file based on the filing date. We further believe that our ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product," the company said.
Tracleer is indicated for treatment of pulmonary arterial hypertension, it added.
